-
1
-
-
70450265301
-
Complement: Coming full circle
-
10.1007/s00005-009-0047-4
-
Friec GL, Kemper C. Complement: coming full circle. Arch Immunol Ther Exp (Warsz). 2009;57(6):393-407.
-
(2009)
Arch Immunol Ther Exp (Warsz)
, vol.57
, Issue.6
, pp. 393-407
-
-
Friec, G.L.1
Kemper, C.2
-
2
-
-
1542357604
-
Identification of tumor antigens and T-cell epitopes, and its clinical application
-
DOI 10.1007/s00262-003-0479-3
-
Paschen A, Eichmuller S, Schadendorf D. Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother. 2004;53(3):196-203. (Pubitemid 38328042)
-
(2004)
Cancer Immunology, Immunotherapy
, vol.53
, Issue.3
, pp. 196-203
-
-
Paschen, A.1
Eichmuller, S.2
Schadendorf, D.3
-
3
-
-
0022982447
-
Membrane alterations in cancer cells: The role of oxy radicals
-
3555261 10.1111/j.1749-6632.1986.tb46579.x 1:CAS:528:DyaL2sXkvFCnsbg%3D
-
Galeotti T, Borrello S, Minotti G, Masotti L. Membrane alterations in cancer cells: the role of oxy radicals. Ann N Y Acad Sci. 1986;488:468-80.
-
(1986)
Ann N y Acad Sci
, vol.488
, pp. 468-480
-
-
Galeotti, T.1
Borrello, S.2
Minotti, G.3
Masotti, L.4
-
4
-
-
0033368042
-
Complement resistance of tumor cells: Basal and induced mechanisms
-
DOI 10.1016/S0161-5890(99)00115-7, PII S0161589099001157
-
Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol. 1999;36(13-14):929-39. (Pubitemid 30100845)
-
(1999)
Molecular Immunology
, vol.36
, Issue.13-14
, pp. 929-939
-
-
Jurianz, K.1
Ziegler, S.2
Garcia-Schuler, H.3
Kraus, S.4
Bohana-Kashtan, O.5
Fishelson, Z.6
Kirschfink, M.7
-
5
-
-
84878919900
-
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
-
23219151 10.1016/j.ctrv.2012.10.008 1:CAS:528:DC%2BC38Xhsl2ju7vI
-
Okroj M, Osterborg A, Blom AM. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat Rev. 2013;39(6):632-9.
-
(2013)
Cancer Treat Rev
, vol.39
, Issue.6
, pp. 632-639
-
-
Okroj, M.1
Osterborg, A.2
Blom, A.M.3
-
6
-
-
79955011744
-
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
-
10.2741/3688
-
Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci. 2010;16:277-306.
-
(2010)
Front Biosci
, vol.16
, pp. 277-306
-
-
Winiarska, M.1
Glodkowska-Mrowka, E.2
Bil, J.3
Golab, J.4
-
7
-
-
0042236333
-
Rituximab in B-cell chronic lymphocytic leukemia
-
DOI 10.1016/S0093-7754(03)00239-2
-
Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol. 2003;30(4):483-92. (Pubitemid 36999690)
-
(2003)
Seminars in Oncology
, vol.30
, Issue.4
, pp. 483-492
-
-
Lin, T.S.1
Lucas, M.S.2
Byrd, J.C.3
-
8
-
-
0035760902
-
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59
-
11719378 10.1182/blood.V98.12.3383 1:CAS:528:DC%2BD3MXovVSgsb8%3D
-
Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383-9.
-
(2001)
Blood
, vol.98
, Issue.12
, pp. 3383-3389
-
-
Golay, J.1
Lazzari, M.2
Facchinetti, V.3
Bernasconi, S.4
Borleri, G.5
Barbui, T.6
-
9
-
-
79952278698
-
Ofatumumab: A new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia
-
21030349 10.3816/CLML.2010.n.069
-
O'Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10(5):361-8.
-
(2010)
Clin Lymphoma Myeloma Leuk
, vol.10
, Issue.5
, pp. 361-368
-
-
O'Brien, S.1
Osterborg, A.2
-
10
-
-
84871831846
-
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy
-
23225880 10.4049/jimmunol.1202645 1:CAS:528:DC%2BC38XhvV2ks7%2FI
-
Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190(1):231-9.
-
(2013)
J Immunol
, vol.190
, Issue.1
, pp. 231-239
-
-
Bologna, L.1
Gotti, E.2
Da Roit, F.3
Intermesoli, T.4
Rambaldi, A.5
Introna, M.6
-
11
-
-
84859402731
-
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients
-
22368276 10.4049/jimmunol.1103693 1:CAS:528:DC%2BC38XksVOltbw%3D
-
Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol. 2012;188(7):3532-41.
-
(2012)
J Immunol
, vol.188
, Issue.7
, pp. 3532-3541
-
-
Beurskens, F.J.1
Lindorfer, M.A.2
Farooqui, M.3
Beum, P.V.4
Engelberts, P.5
Mackus, W.J.6
-
12
-
-
84878909091
-
Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia
-
Middleton O, Cosimo E, Dobbin E, McCaig AM, Clarke C, Brant AM, et al. Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia. Immunology. 2012;137(Suppl. 1):196.
-
(2012)
Immunology
, vol.137
, Issue.SUPPL. 1
, pp. 196
-
-
Middleton, O.1
Cosimo, E.2
Dobbin, E.3
McCaig, A.M.4
Clarke, C.5
Brant, A.M.6
-
13
-
-
84865367405
-
Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
-
10.1002/ajh.23273 22718493 10.1002/ajh.23273 1:CAS:528:DC%2BC38Xht1ekt7zP
-
Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol. 2012;87(9):880-5. doi: 10.1002/ajh.23273.
-
(2012)
Am J Hematol
, vol.87
, Issue.9
, pp. 880-885
-
-
Charbonneau, B.1
Maurer, M.J.2
Fredericksen, Z.S.3
Zent, C.S.4
Link, B.K.5
Novak, A.J.6
-
14
-
-
84867391087
-
Functional analyses of complement convertases using C3 and C5-depleted sera
-
23071769 10.1371/journal.pone.0047245 1:CAS:528:DC%2BC38XhsFOku7fP
-
Okroj M, Holmquist E, King BC, Blom AM. Functional analyses of complement convertases using C3 and C5-depleted sera. PLoS ONE. 2012;7(10):e47245.
-
(2012)
PLoS ONE
, vol.7
, Issue.10
, pp. 47245
-
-
Okroj, M.1
Holmquist, E.2
King, B.C.3
Blom, A.M.4
-
15
-
-
84856249903
-
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
-
22150234 10.1111/j.1365-2141.2011.08966.x 1:CAS:528:DC%2BC38Xks1yisb8%3D
-
Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012;156(4):490-8.
-
(2012)
Br J Haematol
, vol.156
, Issue.4
, pp. 490-498
-
-
Barth, M.J.1
Hernandez-Ilizaliturri, F.J.2
Mavis, C.3
Tsai, P.C.4
Gibbs, J.F.5
Deeb, G.6
-
16
-
-
80455162357
-
RILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia
-
21918174 10.1158/1078-0432.CCR-11-0647 1:CAS:528:DC%2BC3MXhsVWlsr7E
-
Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, et al. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(21):6702-11.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.21
, pp. 6702-6711
-
-
Ge, X.1
Wu, L.2
Hu, W.3
Fernandes, S.4
Wang, C.5
Li, X.6
-
17
-
-
0034660092
-
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
-
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-8. (Pubitemid 30412866)
-
(2000)
Blood
, vol.95
, Issue.12
, pp. 3900-3908
-
-
Golay, J.1
Zaffaroni, L.2
Vaccari, T.3
Lazzari, M.4
Borleri, G.-M.5
Bernasconi, S.6
Tedesco, F.7
Rambaldi, A.8
Introna, M.9
-
18
-
-
33644866786
-
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
-
DOI 10.1016/j.leukres.2005.09.008, PII S0145212605003607
-
Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006;30(5):625-31. doi: 10.1016/j.leukres.2005.09.008. (Pubitemid 43374591)
-
(2006)
Leukemia Research
, vol.30
, Issue.5
, pp. 625-631
-
-
Takei, K.1
Yamazaki, T.2
Sawada, U.3
Ishizuka, H.4
Aizawa, S.5
-
19
-
-
0037306893
-
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
-
DOI 10.1182/blood-2002-02-0469
-
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101(3):949-54. (Pubitemid 36139365)
-
(2003)
Blood
, vol.101
, Issue.3
, pp. 949-954
-
-
Manches, O.1
Lui, G.2
Chaperot, L.3
Gressin, R.4
Molens, J.-P.5
Jacob, M.-C.6
Sotto, J.-J.7
Leroux, D.8
Bensa, J.-C.9
Plumas, J.10
|